
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is showing strong financial performance with revenue exceeding expectations and gross product sales reaching $11.1M thanks to successful YARTEMLEA launch, demonstrating high demand and formulary access. The company is also focused on expanding YARTEMLEA adoption and has a strong pipeline, with upcoming catalysts expected such as a regulatory decision from the EMA and continued commercial infrastructure development. Risks to consider include clinical, regulatory, partnership, financial, commercial, legal, and market share factors, but the recent J-code assignment and favorable backdrop suggest positive potential for growth in the TA-TMA market.
Bears say
Omeros is a biotechnology company with a pipeline of promising clinical-stage development programs targeting a range of diseases. However, the company has yet to demonstrate significant revenue from its commercialized product, YARTEMLEA, and its other potential treatments are still in early stages of development. With no immediate catalysts to drive significant financial growth, the company's stock may face challenges in the near term.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares